Delucemine

Delucemine

Systematic (IUPAC) name
3,3-bis(3-fluorophenyl)-N-methylpropan-1-amine
Identifiers
CAS Number	186495-49-8
ATC code	none
PubChem	CID 156421
ChemSpider	137745
UNII	124LSR3H2X
ChEMBL	CHEMBL2106165
Chemical data
Formula	C16H17F2N
Molar mass	261.3097 g/mol
SMILES CNCCC(C1=CC(=CC=C1)F)C2=CC(=CC=C2)F
InChI InChI=1S/C16H17F2N/c1-19-9-8-16(12-4-2-6-14(17)10-12)13-5-3-7-15(18)11-13/h2-7,10-11,16,19H,8-9H2,1H3 Key:MUGNLPWYHGOJEG-UHFFFAOYSA-N
(what is this?)  (verify)

Delucemine (NPS-1506) is a drug which acts as an NMDA antagonist and a serotonin reuptake inhibitor, and has neuroprotective effects.^[1][2] It was originally investigated for the treatment of stroke and in 2004 was studied as a potential antidepressant.^[3][4][5]

Origin

The basic structure of Delucemine was based on argiotoxin 636, a NMDA antagonist isolated from the venom of the Araneid Argiope aurantia.^[6][7][8]

See also

• AD-1211
• Budipine
• Diphenidine
• Ephenidine
• Fluorolintane
• Lanicemine
• Methoxphenidine
• MT-45
• Remacemide

References

1. Mueller AL, Artman LD, Balandrin MF, Brady E, Chien Y, Delmar EG, George K, Kierstead A, Marriott TB, Moe ST, Newman MK, Raszkiewicz JL, Sanguinetti EL, van Wagenen BC, Wells D. (December 1999). "NPS 1506, a novel NMDA receptor antagonist and neuroprotectant. Review of preclinical and clinical studies.". Annals of the New York Academy of Sciences 890: 450–457. doi:10.1111/j.1749-6632.1999.tb08023.x. PMID 10668449.
2. Matthew J. Leoni, Xiao-Han Chen, Alan L. Mueller, Jessica Cheney, Tracy K. McIntosh, Douglas H. Smith (December 2000). "NPS 1506 attenuates cognitive dysfunction and hippocampal neuron death following brain trauma in the rat.". Experimental Neurology 166 (2): 442–449. doi:10.1006/exnr.2000.7513. PMID 11085909.
3. NPS Pharmaceuticals Inc NPSP Quarterly Report
4. Robert Pyke, Angelo Ceci. "Patent CA 2599721 A1 - Pharmaceutical compositions for the treatment and/or prevention of depression". Retrieved 24 June 2015.
5. Fumito Ichinose, Eizo Marutani, Kotaro Kida. "Patent WO 2014015047 A1 - Compositions and methods to treat neurodegenerative diseases". Retrieved 24 June 2015.
6. Nentwig, Wolfgang (2013-02-15). Spider Ecophysiology. Springer Science & Business Media. ISBN 9783642339899.
7. Vera Oldrati, Estelle Bianchi, Reto Stöcklin (February 2013). "Spider Venom Components as Drug Candidates". Spider Ecophysiology: 491–503. doi:10.1007/978-3-642-33989-9_37.
8. Victoria Monge-Fuentes, Flávia Maria Medeiros Gomes, Gabriel Avohay Alves Campos, Juliana de Castro Silva, Andréia Mayer Biolchi, Lilian Carneiro dos Anjos, Jacqueline Coimbra Gonçalves, Kamila Soares Lopes, Márcia Renata Mortari (August 2015). "Neuroactive compounds obtained from arthropod venoms as new therapeutic platforms for the treatment of neurological disorders". Journal of Venomous Animals and Toxins including Tropical Diseases 21 (31). doi:10.1186/s40409-015-0031-x. PMC 4529710. PMID 26257776.